Weight trajectories after last Tirzepatide or Semaglutide prescription across a federated health network

Competing Interest Statement

The authors are employees or advisors of nference, inc., which conducts research collaborations with various biopharmaceutical companies, including AstraZeneca, Eli Lilly and Company, and Novo Nordisk A/S, whose GLP-1 receptor agonist products (semaglutide and tirzepatide formulations) are included in this study. None of these companies, nor any other nference collaborator, funded, supported, or had any role in the independent study design, data acquisition, analysis, interpretation, manuscript preparation, or the decision to submit this work for publication. All analyses were conducted by the authors using de-identified electronic health record data. The authors declare no additional competing interests.

Funding Statement

This study did not receive any external funding. The authors did not receive payment or services from any third party for any aspect of the submitted work, including study design, data acquisition, analysis, interpretation, manuscript preparation, or statistical analysis.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study analyzed de-identified EHR data from a network of tertiary clinical centers tied to academic medical centers in the United States through the nference nSights Analytics Platform. nference, in collaboration with academic medical center (AMC) data partners, provided the de-identified data for this study. nference has established a secure data environment, hosted by and within each of the AMCs, that contain the AMCs de-identified patient data. The provisioning of and access to this data are governed by an expert determination that satisfies the HIPAA Privacy Rule requirements for the de-identification of protected health information. Each AMCs de-identified data environment is specifically designed and operated to enable access to and analysis of de-identified data without the need for Institutional Review Board (IRB) oversight, approval, or an exemption confirmation. Given these measures, informed consent and IRB review were not required for this study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes